A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

1.6K views

⸱

DOI:

10.3791/66876

⸱

January 31st, 2025

 ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

This protocol presents a step-by-step guide for performing minimally invasive isolated limb perfusion (MI-ILP), a treatment option for patients with locally advanced melanomas and sarcomas of the extremities.

Abstract

Minimally invasive isolated limb perfusion (MI-ILP) is a treatment option for patients with locally advanced melanomas and sarcomas of the extremities. Briefly, the procedure starts with percutaneous access of the femoral or brachial vessels in the diseased extremity. It is then isolated from the rest of the body with a tourniquet. The catheters are connected to a heart-lung machine, and the extremity is perfused with a high dose of melphalan. In the literature, the reported overall and complete response rates for ILP are approximately 80% and 60%, respectively. Our previously reported results using MI-ILP, showed similar response rates. The objective of this manuscript is to provide a step-by-step guide on how to perform an MI-ILP. The purpose of this protocol is to enable local perfusion of the extremities with a high dose of chemotherapy without systemic leakage in a minimally invasive manner.

Introduction

The global incidence of melanoma is increasing and is particularly pronounced in the Western population, where one out of every 50 individuals will develop melanoma1. Patients with cutaneous melanoma can develop in-transit metastasis (ITM), most often localized to the limb2. These metastatic deposits appear as discrete tumor nodules within the subcutaneous or cutaneous tissue and arise between the primary melanoma site and the nearest regional lymph node basin. A compelling hypothesis implies that ITM develops after the entrapment and subsequent proliferation of tumor cell emboli in dermal lymphatic vessels between the p....

Access restricted. Please log in or start a trial to view this content.

Protocol

The protocol adheres to the guidelines established by our Institution's Human Research Ethics Committee.

1. Anesthesia

  1. Induce anesthesia according to the Institute's local protocol.

2. Set up

  1. Calculate the leg volume of the patient (1 day preoperative):
    1. Lay the patient supine and draw a circular baseline starting in the groin. With 5 cm intervals, mark the patient's leg down to the ankle.
    2. If there is evidence of tumor load in the foot, include foot measurements by adding the length from the heel of the patient to t....

Access restricted. Please log in or start a trial to view this content.

Results

We have previously published the results of the first six patients treated with MI-ILP (five femoral and one brachial) between June 2016 and March 2017 at Sahlgrenska University Hospital11. Patients who were 18 years or older with a locally advanced tumor of the extremity that had an indication for ILP were included in the study. Patients were excluded if they had a previous lymph node dissection, current lymph node disease, or severe atherosclerosis, as this could potentially complicate percutane.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Patients with ITM have a poor prognosis and their treatment remains challenging. A key factor in treating these patients is aiming for local control. In a minority of these patients, surgical excision can be used when the tumor load is limited. When patients have more extensive disease or when ITMs are rapidly recurring, surgical resection is not possible. In these patients, isolated limb perfusion is an effective treatment option, with a high overall response rate of around 80%10. Despite its hig.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

Roger Olofsson Bagge has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag), SkyLineDx and NeraCare GmbH, speaker honorarium from Roche, Pfizer and Pierre-Fabre, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Cansr.com, Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme, and is a shareholder in SATMEG Ventures AB.

Acknowledgements

Polle Willemsen (filmer and producer) is acknowledged for excellent video recording and editing of the movie.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
0.018” introducer guidewire 
0.035” exchange guidewire 
10-12Fr BioMedicus Nextgen Pediatric Arterial cannulae. Medtronic, Minneapolis, MN, USA96820-110 (10Fr); 96820-112 (12Fr)
12-14 Fr BioMedicus  NextGen Pediatric Venous Cannulae Medtronic, Minneapolis, MN, USA96830-112 (12Fr); 96830-114 (14Fr)
Esmarch tourniquets McKesson 16-50409
Micro-introducer, 4 Fr, 10 cm MAK, Merit Medical, USA MAK401 Includes: (1) Co-axial introducer/dilator pair; (2) 21G Needle; (3) Guide wire
PerClose ProGlide closure devicesAbbott 12773-02Includes:  (1)Perclose Suture-Mediated Closure and repair device; (2) suture trimmer; (3) snared knot pusher 
Special Needle (20G, 12 cm) Mediplast AB, Sweden662620091

References

  1. Arnold, M., et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 158 (5), 495-503 (2022).
  2. Pawlik, T. M., et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. A....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Minimally Invasive ILPMelanoma In-Transit MetastasisExtremity SarcomaPercutaneous Vascular AccessMelphalan PerfusionHeart-Lung MachineTourniquet IsolationLeakage MonitoringInterventional Radiology